Lipid lowering drugs prescription and the risk of peripheral neuropathy: An exploratory case-control study using automated databases

Journal of Epidemiology and Community Health

Volumn 58, Issue 12, 2004, Pages 1047-1051

  Corrao, Giovanni ^a   Zambon, Antonella ^a   Bertù, Lorenza ^a   Botteri, Edoardo ^a   Leoni, Olivia ^b   Contiero, Paolo ^c  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b Loc Hlth Dept of the Prov Varese   (Italy)

^c Loc Hlth Dept of the Prov Varese ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; BEZAFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; SIMVASTATIN; STATINE DERIVATIVE;

CARDIOVASCULAR DISEASE; DATABASE; DRUG USER;

ADULT; ARTICLE; AUTOMATION; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CONTROLLED STUDY; DATA BASE; DRUG EXPOSURE; FEMALE; HUMAN; ITALY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PERIPHERAL NEUROPATHY; PRESCRIPTION;

ADULT; AGE FACTORS; AGED; ANTILIPEMIC AGENTS; CASE-CONTROL STUDIES; CLOFIBRIC ACID; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ITALY; MALE; MEDICAL RECORD LINKAGE; MIDDLE AGED; PERIPHERAL NERVOUS SYSTEM DISEASES; PRESCRIPTIONS, DRUG; SEX FACTORS;

EID: 9444232789     PISSN: 0143005X     EISSN: None     Source Type: Journal    
DOI: 10.1136/jech.2003.013409     Document Type: Article

References (28)

1. Strom BL. Pharmacoepidemiology. 3rd ed. New York: Wiley, 2000.
2. Petri H, Leufkens H, Naus J, et al. Rapid method for estimating the risk of acutely controversial side effects of prescription drugs. J Clin Epidemiol 1990;43:433-9.
3. Suissa S. Pharmacoepidemiology, overview, In: Gail MH, Benichou J, eds. Encyclopedia of epidemiologic method. New York: Wiley, 2000:702-12.
4. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326:1423.
5. Muldoon MF, Manuck SB, Mathews KA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ 1990;310:309-14.
6. Jacobs MB. HMG-CoA reductase inhibitor therapy and peripheral neuropathy. Ann Intern Med 1994;120:970.
7. Ahmad S. Lovastatin and peripheral neuropathy. Am Heart J 1995;130:1321.
8. Phan T, McLeod JG, Pollard IJ, et al. Peripheral neuropathy associated with simvastatin. J Neurol Neurosurg Psychiatry 1995;58:625-8.
9. Jeppesen U, Gaist D, Smith S, et al. Statins and peripheral neuropathy. Eur J Clin Pharmacol 1999;54:835-8.
10. Gaist D, Garcia Rodriguez LA, Huerta C, et al. Are users of lipid-lowering drugs at increased risk of peripheral neuropathy? Eur J Clin Pharmacol 2001;56:931-3.
11. Gaist D, Jeppesen U, Andersen M, et al. Statins and the risk of polyneuropathy. A case-control study. Neurology 2002;58:1333-7.
12. Gabriel R, Pearce JMS. Clofibrate induced myopathy and neuropathy. Lancet 1976;ii:906.
13. Argov O, Mastaglia FL Drug-induced peripheral neuropathy. BMJ 1979;1:663-6.
14. Ellis CJ, Wallis WE, Caruana M. Peripheral neuropathy with bezafibrate. BMJ 1994;309:929.
15. Corcia P, De Toffol B, Hommet C, et al. Severe toxic neuropathy due to fibrates. J Neurol Neurosurg Psychiatry 1999;66:410.
16. WHO Collaborating Center for Drug Statistics Methodology. ATC classification index including defined doses for plan substances. Oslo: WHO, 1995.
17. Breslow NE, Day NE. Statistical methods in cancer research. Vol I The analysis of case-control studies. IARC Scientific Publications no 32. Lyon: International Agency for Research on Cancer, 1980.
18. Hosmer DW, Lemeshow S. Applied logistic regression. New York: Wiley, 1989.
19. SAS Institute Inc. SAS technical report P-229, SAS/STAT software: changes and enhancements, release 6.07. Cary, NC: SAS Institute, 1992.
20. Italian Health Department. http://www.ministerosalute.it/programmazione/ sdo/sdo.jsp.
21. King H, Rewers M, and WHO Ad Hoc Diabetes Reporting Group. Global estimate for prevalence of diabetes mellitus and impaired glucose tolerance in adults. Diabetes Care 1993;16:157-77.
22. Fischbacher C, Bhopal R, Patel S, et al. Anaemia in Chinese, South Asian, and European populations in Newcastle upon Tyne: cross sectional study. BMJ 2001;322:958-9.
23. Magnason RL, Indridason OS, Sigvaldason H, et al. Prevalence and progression of CRF in Iceland: a population-based study. Am J Kidney Dis 2002;40:955-63.
24. Evans JMM, MacDonalds M. Misclassification and selection bias in case-control studies using an automated database. Pharmacoepidemiol Drug Safe 1997;6:313-18.
25. Brenner H, Savitz DA. The effects of sensitivity and specificity of case selection on validity, sample size, precision, and power in hospital-based case-control studies. Am J Epidemiol 1990;132:181-92.
26. Brenner H, Gefeller O. Use of the positive predictive value to correct for disease misclassification in epidemiologic studies. Am J Epidemiol 1993;138:1007-15.
27. MacDonald BK, Cockerell OC, Sounder WAS, et al. The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. Brain 2000;123:665-76.
28. Copeland KT, Checkoway H, McMichael AJ, et al. Bias due to misclassification in the estimation of relative risk. Am J Epidemiol 1977;105:488-95.